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Aging is a complex process that affects all living organisms. As we age, the biological functions are 
affected, resulting in a decline of the tissue and possibly age-related diseases. Several environmental 
and genetic factors have been suggested to contribute to aging. Among these factors, a progressive 
loss of genome integrity, caused by the occurrence of somatic mutations, is proposed as a cause of 
deterioration of cellular functions. The aim of this thesis was to analyze the effect of somatic 
mutations in healthy cells and analyze the contribution of somatic mutations to age-related diseases. 
In paper I, we showed that satellite cells, stem cells of the skeletal muscle, accumulate 13 somatic 
mutations per genome per year during adult life. Although genes expressed in the skeletal muscle 
were protected from mutations by the DNA repair machinery, we observed that this protection was 
less efficient at increased age, resulting in higher mutation load in the exons of old compared to young 
satellite cells. A somatic mutation identified in a satellite cell was also detected in a small percentage 
of the cells of the muscle biopsy, suggesting that somatic mutations propagate from satellite cells to 
the differentiated muscle during adult age and might contribute to its age-related decline.  
In paper II, we created a genetic atlas of somatic mutations in healthy cells from different tissues 
based on newly generated and publicly-available sequencing data. In contrast to the current view of a 
tissue-specific mutational profile, several cell types showed the same mutational profile despite 
coming from different tissues. Furthermore, two distinct cell types from the same tissue showed 
different mutational profiles and rates of mutation accumulation. Thanks to these data, we identified 
multiple factors influencing mutagen exposure and consequent mutational profiles. These factors 
include the cell´s localization within the tissue, the degree of differentiation and the presence of a 
protective stem cell niche. In addition, we identified an epithelial cell of the kidney that shows a 
unique distribution of mutations, characterized by mutation enrichment in highly transcribed genes. 
This pattern increases the chances of mutating a cancer-driver gene and is in agreement with an 
increased predisposition to cancer in this cell type. Finally, our analyses provide evidence of a decline 
of DNA-repair with aging. 
In paper III, we identified somatic mutations in the brain of Alzheimer´s disease (AD) patients. Using 
ultra-deep sequencing and tailored bioinformatics analysis, we could detect low-frequency variants in 
bulk tissue. In total, 2.86 Mb of candidate genes and AD-linked genomic regions were included in the 
study, and 11 somatic single nucleotide variants (SNVs) were identified in AD brains, but none in 
non-AD brains. One variant was validated and predicted to affect transcription factor binding sites 
upstream of the CD55 gene, possibly contributing to AD through the regulation of the complement 
system.  
In paper IV, we showed that patients with end-stage chronic kidney disease (CKD) express progerin 
within their arterial media, the same mutated form of the protein lamin A found in premature aging 
patients. Importantly, we could identify the mutation that causes progeria, the LMNA c.1824C>T, in 
DNA extracted from the arteries. In total, we could identify the progerin protein or the mutation in 34 
of the 40 CKD patients. DNA damage and increased proliferation were detected in the CKD patients, 
indicating extensive vascular regeneration. Our result suggests that progenitor cells carrying LMNA 
c.1824C>T contribute to the vascular pathology and thereby to the disease progression observed in 
CKD patients. 
In conclusion, the work presented in this thesis provides a new understanding of the contribution of 
mutation accumulation in healthy cells with possible implications for aging and age-associated 
diseases. 
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1 INTRODUCTION 
1.1 AGING  
During the last century the life expectancy has dramatically increased. At the beginning of 
19th century life expectancy was around 50 years, but it is now over 80 years in western 
societies (1, 2). Improved life qualities, where people have access to better health care and 
food has led to increased life expectancy and a higher proportion of older individuals. Today, 
12% of the world population is at least 60 years of age, and this percentage is expected to rise 
to 22% by the year 2050 (2).  
Aging is a complex process that affects most biological functions and results in tissue decline. 
As the individual gets older, the likelihood of age-related diseases increases. The incidences 
of several diseases, such as cancer and cardiovascular diseases, dramatically increase after the 
age of 60 (3). Although twin studies have shown that heritability of human aging is 20-30% 
(4), few genetic factors contributing to aging are known. Genome-wide association studies on 
centenarians, longevity and healthy aging individuals have revealed that aging is a complex 
trait with several candidate genes but few well-replicated genes (5-7). The SIRT1, LMNA and 
CDKN2A/B are among the genes that have been linked with longevity and aging (8-10), but 
the strongest association has been observed in the APOE and the FOXO3A genes (6, 9, 11, 
12). It has been suggested that healthy aging is due to reduced genetic risk or even protection 
against age-related diseases (7). Indeed, a variant in chromosome 5q33.3 linked to longevity, 
is associated with low blood pressure and reduced risk of death from a stroke (6). 
Several factors have been suggested to contribute to aging, and summarized in nine hallmarks 
of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, 
deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell 
exhaustion and altered intercellular communication (13). These nine hallmarks have been 
divided into three categories: primary, antagonistic and integrative hallmarks (Figure 1). The 
primary hallmarks (genomic instability, telomere attrition, epigenetic alterations and loss of 
proteostasis) have adverse effects on the cells and are contributed, among others, by 
exogenous and endogenous DNA damage and inefficient DNA repair machinery. That leads 
to antagonistic hallmarks (deregulated nutrient sensing, mitochondrial dysfunction and 
cellular senescence) as responses to the damage and finally to integrative hallmarks (stem cell 
exhaustion and altered intercellular communication) as a result of the previous two (13).  
One way to study the hallmarks of aging is to analyze premature aging syndromes (also 
known as progeroid syndromes) like Hutchinson-Gilford Progeria Syndrome (HGPS; OMIM 
176670) (14-16), Werner syndrome (OMIM 277700) (17) and xeroderma pigmentosum 
(OMIM 278700) (18). These disorders show many features of physiological aging and share 
many of the hallmarks previously linked to aging (genome instability, telomere dysfunction, 
epigenetic changes, nuclear lamina alterations, cell cycle deregulation, senescence, metabolic 
defects, inflammation, stem cell exhaustion) (19). Several in vitro and in vivo models are 
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available for these disorders (19) that can be used to achieve better understandings of not only 
the progeroid syndromes but aging as well.  
 
Figure 1: Hallmarks of aging (13). Primary hallmarks: Genomic instability, telomere 
attrition, epigenetic alterations and loss of proteostasis are believed to be the primary cause of 
damage. Antagonistic hallmarks: Deregulated nutrient sensing, mitochondrial dysfunction 
and cellular senescence are considered as a response to damage. Integrative hallmarks: Stem 
cell exhaustion and altered intercellular communication are the end result of the previous two, 
resulting in functional decline with aging. 
1.2 MUTATIONS IN THE HUMAN GENOME 
The human genome can harbor two types of mutations, germline and somatic. Germline 
mutations are found in the first cell of the embryo and propagate to every cell of an 
individual. Conversely, somatic mutations are acquired by each cell lineage during 
development and post-natal life. For this reason, somatic mutations are found only in a 
portion of the cells of an individual, or even in a single cell (Table 1).  
Table 1: Comparison on germline and somatic mutations 
Germline mutations Somatic mutations 
Found in every cell in the body Most often occurring in single cells 
Affecting all tissues Most often only found in part of a tissue 
Inherited from parents or  
acquired during gametogenesis 
Acquired during development or  
anytime during life  
Transmitted to offspring Usually not transmitted to offspring 
Effects the evolution Do not have an effect on the evolution 
Mutation rate  
1.2 × 10−8 mutations per bp (20) 
Mutation rate  
2.8 × 10−7 mutations per bp (20) 
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Somatic mutations finally convert every tissue into a mosaic of cells, each carrying its unique 
genome (21-34). The frequency of a newly acquired mutation in the tissue depends on when 
the mutation arises. Mutations arising early during embryogenesis can be detected in 
substantial percentages of the cells and multiple tissues, while mutations acquired later in the 
lifespan usually affect fewer cells (Figure 2). It is unclear what effect somatic mutation 
accumulation has on the tissue and how it contributes to the decline of tissue homeostasis. 
However, it has been proposed to contribute to aging and diseases.  
 
Figure 2: The frequency of the somatic mutations depends on when the mutation arises. 
Mutations arising early during embryogenesis are usually found in multiple tissues and in a 
high percentage of the cells composing each tissue. Mutations occurring after birth are 
usually found in individual cells. Only if mutations are in the germ cells they will be 
transferred to the offspring. 
Different mutation types have a different impact on the cell depending on their size and 
genomic location. Mutations range from single nucleotide mutations to large genetic 
alterations, or even to a gain or a loss of a whole chromosome (22). Larger genetic alterations 
are rarer but affect more bases, while single base substitutions are common but only affect 
one nucleotide (34). Mutations in the coding regions can have severe consequences for the 
cell; however, non-coding regions, even if mutated or lost, are unlikely to cause a significant 
effect on the cell. Nevertheless, it is becoming more apparent that within these non-coding 
regions are regulatory regions that are important for cell function (35).  
Mutations occur continuously and randomly hit the genome during our lifetime. DNA 
damage can be due to exogenous or endogenous mutagens. Examples of exogenous mutagens 
are ultraviolet (UV) radiation and various chemicals (36), while examples of endogenous 
mutagens are free radicals like reactive oxygen species (ROS), or spontaneous deamination 
of the DNA bases (37, 38). Reactive oxygen species are a result of our metabolism and can 
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lead to over 25 different oxidative DNA lesions where 8-Oxoguanine (8-oxoG) is the best-
studied, leading to G:C>T:A mutations  (39). Spontaneous deamination on cytosine and 5-
methylcytosine in CpG sites are quite frequent and results in C>T mutations (38).  
To counteract this continuous DNA lesions in the genome, we have an efficient repair 
mechanism (37). However, DNA repair does not have the same efficiency in all parts of the 
genome (39-41). During cell replication, the most vital genomic regions are replicated first 
and the least essential regions last (42). The mutation rate is increased in the later replicated 
regions (43, 44) indicating a selective repair mechanism. That is due to differential mismatch 
repair mechanisms (MMR) (40, 41) and transcription-coupled repair (39) that protect exons 
and regions necessary for the cell existence and function. During aging, the repair mechanism 
declines (45) contributing to increased mutational burden observed in older individuals, and 
to aging and age-related diseases as cancer (37, 39, 46).  
Somatic mutations have been suggested to contribute to the regeneration of injured tissue 
(47). Studies on the liver and the esophagus have reported frequently mutated genes that 
promote proliferation without leading to tumor formation (24, 47). Furthermore, somatic 
mutations can rescue the cell from pathogenic mutations in a mechanism called revertant 
mosaicism (22) or somatic genetic rescue (48). This process involves mutations or 
recombination, resulting in a regain of the wild-type genotype or diminished effect of the 
pathogenic mutation. The acquired mutation can give the cell an increased fitness resulting in 
clonal expansion of that cell and generate somatic mosaicism within the tissue (47, 48).  
Germline variants can contribute to somatic mutagenesis. Cancer provides the best-known 
examples where germline variants lead to increased mutational burden and specific somatic 
mutation patterns, as can be seen for variants in the APOBEC gene family or the BRACA 
genes (49, 50). Also, patients with xeroderma pigmentosum, caused by variants in DNA 
repair genes, have up to a 2.5 fold increased somatic mutagenesis compared to age-matched 
controls (27). Germline variants can indirectly lead to increased mutagenesis. Individuals 
carrying a nicotine-addiction variant have an increased risk of smoking (51), which creates a 
toxic environment for the cells, increased mutational burden, and tumorigenesis.  
Although somatic mutations are not transmitted to the offspring, pathogenic mutations have 
been identified at a lower frequency in parents of affected offspring (52-56). For example, 
germline mutations in children with osteogenesis imperfecta and HGPS have been found as 
low-level somatic mutations in parents. That can result in a milder phenotype in the parent 
and recurrence of the disease among siblings (55-57). 
1.3 METHODS TO IDENTIFY SOMATIC MUTATIONS 
Identifying somatic mutations in the genome is more challenging than to identify germline 
mutations. Germline mutations are present in every cell and can be assessed in any bulk 
tissue. Most studies on germline mutations are conducted on blood DNA due to easy access. 
However, when identifying tissue-specific somatic mutations, tissue accessibility is a limiting 
factor, as well as the frequency of the mutations in the tissue.  
   5 
The specificity and sensitivity of the mutation detection depend on the experimental method 
used and the bioinformatics analysis. The main experimental methods to identify somatic 
mutations are: i) in vitro clonal expansion of progenitor cells, ii) single-cell DNA (scDNA) 
and single-cell RNA (scRNA) sequencing and iii) bulk tissue analysis using ultra-deep 
targeted sequencing, exome sequencing, whole-genome sequencing or droplet digital PCR 
(ddPCR) (Figure 3). All these methods have pros and cons. The first two methods (clonal 
expansion and single-cell sequencing) give the possibility to identify mutations unique for 
every cell and to compare the mutagenesis between different cell types. Conversely, bulk 
tissue analyses only allow the detection of mutations that are found in a high percentage of 
cells in the tissue (>5% allele fraction in standard exome sequencing (58)). Additionally, bulk 
tissue often consists of several cell types. Therefore, it is not possible to identify what cell 
type is carrying the mutations detected, while specific cell types can be selected using the first 
two methods. The first method relies on progenitor or progenitor-like cells that need to be 
clonally expanded in culture, while post-mitotic cells can be analyzed with the other two 
methods. 
 
Figure 3: Three different methods to identify somatic mutations in tissues. Single-cell 
suspensions obtained from a tissue biopsy can either be i) clonally expanded in culture prior 
to whole-genome sequencing, or ii) single-cell DNA (scDNA) or RNA (scRNA) 
sequenced. iii) DNA can be isolated from a bulk biopsy for ultra-deep genome sequencing, 
exome sequencing, whole-genome sequencing or droplet digital PCR (ddPCR). 
Identifying somatic mutations in single cells reveals the mutation load and pattern in different 
cell types and the relationship between cell lineages within a tissue.  Several studies have 
been reported on cell-specific somatic mutations identified with clonal expansion of 
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progenitor cells (21, 30, 32, 59) or with scDNA (27, 28, 33, 60) or scRNA (61, 62) 
sequencing. These methods are based on the tissue being disrupted to obtain a single-cell 
suspension. That can be challenging depending on the tissue. Obtaining single-cell 
suspension from hard tissues like bones is more difficult than from soft tissues like the brain. 
The tissue sources are limited, and long-time storage can affect the quality of the DNA or 
RNA. Furthermore, cell types need to be known prior to sequencing. With RNA sequencing, 
cell types can be identified based on the expression values, but DNA sequencing does not 
provide such information about cell types. Therefore, cells need to be fluorescence-activated 
cell sorted (FACS) or tested in other ways before sequencing.  
Since the clonally expanded progenitor cells are the clones of the same original cell, all 
variants that occurred prior to the in vitro cell culture are expected to have an allele frequency 
of 50%. The cells are expanded in culture to obtain enough DNA to get good genomic 
coverage and complexity. However, there is an increased risk of culture-induced variants that 
can affect the results. One approach to avoid bias from culture-induced variants is to analyze 
the distribution of allele frequency in the sample and set a threshold to avoid false variants. 
As well it needs to be kept in mind that growing cells in culture can lead to selection bias of 
cells carrying beneficial mutations. On the other hand, scDNA sequencing cells have no 
culture-induced mutations but need to be whole genome amplified. That can result in a high 
error rate (23, 34), among others, due to the limited DNA input leading to allelic imbalance, 
allelic dropout or false-positive calls (63). 
Another approach is to simultaneously do gene expression analysis and mutation analysis in 
scRNA sequencing using SMART-Seq2 (61) or 10X Chromium (62). This approach can only 
detect variants in expressed genes, which is a small portion of the genome. In addition, these 
methods are less advanced than those based on DNA sequencing. ScRNA sequencing has 
high error rates due to reverse transcription of RNA to cDNA, and cDNA amplification prior 
to sequencing (61, 64). Furthermore, gene expression values can vary depending on the 
condition the cells are in, or between different experiments (64) and that affects the 
identification of somatic mutations. It is harder to identify somatic mutations in low-
expressed genes since they have less sequencing depth than the high-expressed genes. 
Furthermore, bioinformatics analysis needs to be adjusted to identify somatic mutations in a 
large set of cells, and to link that to the transcriptomic data (62, 64).  
When identifying rare somatic mutations in bulk DNA, specific questions or analyses of 
specific cell types are more beneficial. Such as to search for parental mosaicism of siblings 
with the same rare disease (52-56) or to search for mutations in candidate genes linked with 
the Alzheimer´s disease (AD; OMIM 104300) (65-68). Then, ddPCR (69) is valuable since it 
is a sensitive method to identify rare mutations (<1% allele frequency) in a bulk tissue (70). 
Another option is to use laser capture microdissection (LCM) to select cells of interest to 
enrich for particular cell types (29, 31, 71). The cells of interest are isolated from the tissue 
and genomic DNA extracted from the compiled cells to obtain enough for deep sequencing.  
With this method, colorectal crypts (29) and neurons in the brain (71) have been analyzed.  
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Bulk DNA sequencing generally has low error-rate and high genomic coverage, however, it 
has limits on how rare mutations can be identified and to obtain genome-wide sequence data 
of high depth can be costly. An average read depth of 30X coverage is sufficient to detect 
germline mutations in whole-genome sequencing. However, low-frequency somatic 
mutations are not easily detected and deeper sequencing is needed (<5% allele fraction in 
standard exome sequencing at 100X-150X coverage (58)).  
Downstream bioinformatic analyses need to be tailored to different methods to be able to 
identify the somatic mutations. Several somatic variant callers such as MuTect1 (58), 
MuTect2 (58), Varscan2 (72) and Strelka2 (73) have been developed to identify somatic 
mutations in the cancer genome. They are more specific and sensitive than the germline 
mutation callers and use a reference sample to filter out the germline mutations. The mutation 
identification needs to be strict to avoid false-positive calls and contamination, but not too 
strict to induce false-negative calls. When identifying low-frequency somatic mutations in a 
non-cancer tissue, and when the sequencing depth is more than usually used for cancer 
projects, the default settings of the somatic callers can be too strict and need to be tailored.  
1.4 SOMATIC MUTATIONAL PATTERN  
The consequence of each mutation depends among others, on the genomic location. Large 
parts of the genome are non-coding regions where mutations are less likely to have an effect, 
and like previously mentioned, essential regions like exons, are protected from mutations (see 
1.3). By using available databases like the Protein Atlas (74, 75), it is feasible to position the 
mutations in consideration to tissue-expressed genes or regulatory regions to explore 
mutation enrichment or depletion in these regions (76). Furthermore, the effect of each 
mutation can be analyzed using annotation tools, as VEP (77) and snpEff (78), that estimate 
its effect on the genome based on the genomic location and the mutation type. 
Analyzing mutational signatures of somatic mutations is a new field. However, it is becoming 
a custom method to understand the biological mechanism behind somatic mutagenesis. 
Mutagenic compounds leave behind distinct mutational spectra comprised of different 
fractions of substitution types and sequencing context (26, 79-82). The most common method 
to analyze the mutation signatures is the 96-category classification where the tri-nucleotide 
context of the single-nucleotide variant (SNV) is analyzed. The six substitution types (C:G → 
A:T, C:G → G:C, C:G → T:A, T:A → A:T, T:A → C:G and T:A → G:C) and the first bases 
upstream and downstream of the mutation are identified (figure 4A). Each substitution type 
can appear in 16 different sequencing contexts, leading to 96 different tri-nucleotide contexts. 
For instance, the C>T mutation with adenine (A) at 5’ and guanine (G) at 3’ end is marked as 
A[C>T]G.  
Mathematical analysis on these mutational spectra in the cancer genomes has revealed several 
mutational signatures (26, 79-82). An earlier version of the cancer signature catalog 
constituted of 30 signatures (80) and a recent version has identified 49 signatures for single-
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base-substitution (SBS), 11 signatures for double-base-substitutions (DBS) and 17 signatures 
for small insertions and deletion (ID) (81).  
The signatures have a distinct pattern that can be related to a specific mutagen or biological 
process. Accumulation of C>T mutations, especially CC>TT dinucleotide, are characteristics 
of UV exposure (36). It can be found in sun-exposed skin and are appointed to signature 7 
(Figure 4B, SBS7a). Smoking gives another pattern with an excess of C>A mutations (79) 
and assigned to signature 4 (Figure 4B, SBS4). Signature 5 is characterized by a relative 
“flat” landscape (Figure 4B, SBS5) and has along with signature 1 been linked to aging (26).  
 
Figure 4: A) Tri-nucleotide sequencing context comprises of the substitution type (here 
SNV) and the nearest neighboring bases on 5’ and 3’ site. B) Examples of three signatures, 
SBS4, SBS5 and SBS7a (81). The X-axis mark the 96-categories and Y-axis represents the 
frequency of each category. 
Studies have been conducted to validate and link signatures to specific mutagens, both 
endogenous and exogenous (39, 83-85). In vitro knockout experiments on DNA repair genes 
have validated the involvement of DNA repair pathways to specific signatures (83, 84) where 
MMR deficiency has been shown to be associated with signatures 6, 20 and 26 (84) and 
nucleotide excision repair (NER) to signature 8 (83). Furthermore, a study on environmental 
agents has confirmed solar radiation to signature 7, and mutagens in tobacco smoke to 
signature 4 (85). Nevertheless, many signatures have unknown etiology and further studies 
are needed.  
Mutational signature analysis can be achieved and interpreted in different ways. Signatures 
can be extracted as de novo signatures (86), or compared directly for their similarity to the 
COSMIC signatures (87). The de novo approach allows identification of novel mutational 
processes, which is not possible to do with a direct comparison. However, both methods can 
be biased from overfitting of signatures and obscure differences between the signatures, 
especially those that have a “flat” mutational profile (88). Comparing the mutational 
signatures observed in healthy cells to the ones observed in cancer or knockout cells can 
provide valuable knowledge regarding somatic mutagenesis. 
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1.5 SOMATIC MUTATIONS IN HEALTHY TISSUES 
Recently, several studies have been published on the accumulation of somatic SNVs in 
healthy tissues (21, 24, 27, 29-33, 59, 60). The main aims of the studies were to identify the 
mutation load of cells in different tissues at different ages, as well as to inspect the location 
and pattern of mutagenesis. These studies have either been based on whole-genome 
sequencing of clonally expanded progenitors (21, 30, 32, 59), selected tissue regions (24, 29, 
31) or scDNA sequencing (27, 33, 60).  
Even at birth, acquired somatic mutations can be detected in our cells, and throughout our 
lives, they continue to accumulate mutations (Figure 5A).  Hematopoietic stem and 
progenitor cell (HSPC) in a newborn has around 40 somatic SNVs while in a 63-year old 
individual over 800 somatic SNVs are detected (59). Cell in the intestine of a 3-year old 
individual have accumulated around 250 somatic SNVs, while up to 3500 somatic SNVs are 
detected in an 87-year old individual (21).  
Although most tissues show similar mutation accumulation, there are signs of more rapid 
accumulation in the sun-exposed skin (32) and colorectal crypts (29) (Figure 5A). The cells 
are exposed to different environmental and endogenous factors, and UV radiation could 
explain this mutation burden in the skin sample (32). It could be expected that cells in highly 
proliferating tissues show a higher accumulation rate than slowly proliferating or post-mitotic 
cells; indeed, cancer risk correlates with cell division rate (89, 90). However, brain neurons, 
which are post-mitotic cells, accumulate up to 40 SNVs/year (27), and epithelial cells in the 
esophagus, colon and intestine, which are highly proliferating cells, accumulate 36 
SNVs/year (21, 24) (Figure 4B). Different experimental methods and analysis could explain 
this difference: the neurons are scDNA sequenced (27) while the colon and intestine cells are 
clonally expanded in vitro (21). Nevertheless, defective DNA damage repair mechanism and 
oxidative stress could explain this mutation accumulation in the aging brain cells (27).  
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Figure 5: Somatic SNVs in different human tissues, as reported in representative studies 
and showed in table 2. A) The number of somatic SNVs (y-axis) in different tissues and at 
different ages (x-axis). Cells from the same individual were merged together; each dot in 
the plot represents the average somatic SNVs per cell per individual. B) Average yearly 
increase of somatic SNVs in different tissues of the human body.  
These results need to be taken with some consideration; different experimental methods 
and bioinformatical analyses were performed in these studies and could affect the result. 
Colon, intestine and liver (21), HSPCs (hematopoietic progenitor cells)(59), B-
lymphocytes (33), skin (32), colorectal (29), brain PFC (prefrontal cortex) and 
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Sequencing On Clonally Expanded Progenitors 
Colon WGS 
CEP 
 9-67 21/6 400-3,383 36/year (21) 
Intestine WGS 
CEP 
3-87 14/9 245-3,516 36/year (21) 
Liver WGS 
CEP 
30-55 10/5 771-1,919 36/year (21) 
Blood-HSPCs WGS 
CEP 
0-63 22/7 0-1,014 14/year (59) 
Blood-HSPCs WGS 
CEP 
59 148/1 815–1,210 na (30) 
Skin fibroblasts WGS 
CEP 
58-62 10/2 581-12,743 9-220/year (32) 
Sequencing On Selected Tissue/Genome Regions 
Colorectal epithelial WGS 
LCM 
13-79 571/41 89-14,358 
 
41/year (29) 
Endometrial epithelial WGS 
LCM 
19-81 182/18 225-2,890 28/year (31)  
Esophagus epithelium WGS and 
UDS° 
20-75 844/9 270-3,050*#  36/year* (24) 
Single-cell DNA Sequencing  
B lymphocytes WGS 
SCMDA 
0 - 106 56/14 237-11,765 24/year* (33) 
Fibroblasts WGS 
SCMDA 












15-82 26/6 500-5,800* 40/year (27) 
Study design: WGS: Whole-genome sequencing; CEP: clonally expanded progenitors; LCM: 
laser capture microdissection; SCMDA: single-cell multiple displacement amplification; MDA: 
multiple displacement amplification – single-cell DNA sequencing; UDS°: Ultra-deep targeted 
sequencing on 74 cancer genes and SNPs.  Age: age range of individuals used in the studies; 
Samples/Individuals: number of samples and individuals used in the studies. SNVs per sample: 
range of the SNVs identified in the samples, as reported in the studies, or estimated from figures in 
the citations (marked *). One study reported only the estimated numbers per individual (marked 
#). The SNV rate shows SNVs accumulated every year as reported in the studies, or estimated 
from figures (marked *). HSPCs: Hematopoietic stem and progenitor cells  
Analyses on mutational signatures in healthy cells have revealed that signatures 1 and 5 
increase with aging, and can be found in most tissues (26). However, they are detected in 
different proportions in different cell types (Figure 6). Signature 1 has been suggested to be 
more prominent in cells that have a high proliferation rate, while signature 5 is more 
noticeable in cells that divide slower (21, 59). Comparisons of cells in different tissues 
support this conclusion. The intestinal cells (colon and intestine) are fast-dividing cells and 
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have a higher proportion of signature 1 mutations, while the liver cells that are slow-dividing 
cells have a higher proportion of signature 5 mutations (21) (Figure 6). HSPCs are believed to 
be quiescent and have a higher proportion of signature 5 (59) (Figure 5). Furthermore, 
signature 5 is not observed in infants’ brain neurons but appear with increased age in 
adolescence and adults (27).  
 
Figure 6: The mutational signatures as reported in representative papers: colon, intestine and liver 
(21), HSPCs (hematopoietic progenitor cells)(59), colorectal (29), or estimated from figures: Brain 
PFC (prefrontal cortex) and hippocampus (27), esophagus (24), endometrium (31). Reported 
signatures are from the COSMIC database or de novo signatures (S_B and S_C (27)). These results 
need to be taken with some consideration; different experimental methods and bioinformatical 
analyses were performed in these studies and could affect the outcome. 
As discussed before, early replicating regions and exons are depleted from mutation 
accumulation (see 1.3). This is observed in the liver, colon, small intestine and skin (21, 32), 
although the liver shows less correlation to replication timing than the other tissues (21).  
Opposite to that are the neurons in the prefrontal cortex (PFC) that show mutation enrichment 
in exons, especially in genes involved in neural function, suggesting defective DNA damage 
repair mechanism (27). Furthermore, cancer-associated mutations, or so-called driver 
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mutations, are observed in healthy cells. The cells of the esophagus (24), colorectal (29) and 
endometrium (31) all have mutations linked to cancer in their respective tissues. 
This different mutational signature and mutation load observed in different tissues show that 
both extrinsic factors like sun exposure, as well as intrinsic factors such as defective DNA 
repair mechanisms, affect the cells in a different manner.  
1.6 SOMATIC MUTATIONS IN AGE-ASSOCIATED DISEASE 
The contribution of somatic mutations to cancer is well known. Mutations that hit an 
oncogene or a tumor-suppressor gene can give that cell advantages and increased 
proliferation, leading to tumorigenesis. Many common diseases do not have known genetic 
causes, especially age-related diseases. That has brought up the hypothesis that somatic 
mutations might contribute to the diseases. 
Suggestive pathogenic somatic mutations have been identified in several tissues leading to 
various diseases (54). Larger chromosomal aberrations such as a loss or a gain of a whole 
chromosome, or copy number variants (CNVs) have been linked with diseases (91). Loss of 
chromosome Y has been linked to a shorter lifetime, smoking, cancer and Alzheimer´s 
disease (AD) (92-94).  
Somatic mutations have been linked to brain malformations (95, 96), and neurological 
diseases (96). Studies on the brain tissue have shown that it consists of mosaic cells resulting, 
among others, from transposons (97), CNVs (96) and SNVs (65-68, 98). Although some 
familial genetic risk factors are known to contribute to AD, most cases are of unknown 
causes. Therefore it has been suggested that somatic mutations could be the cause of the 
disease. Identifying somatic mutations in the AD brains is challenging, but recent studies 
have shed light on brain-specific SNVs in AD brains (Table 3).  
While most studies have been focusing on targeted genes (65-68), two exome sequencing 
studies have reported several brain-specific SNVs (71, 98). In a recent study, both ultra-deep 
sequencing (584x) and LCM, to enrich neuronal cells, were used to identify in total 595 
brain-specific SNVs in AD hippocampus. The mutation rate was calculated to be 22 somatic 
SNVs per year, where the mutations were contributed by signature 1, 5 and 18, previously 
linked with aging and oxidative stress (71). In addition, somatic gene recombination in the 
neurons of individuals with AD, as well as in healthy neurons, has been linked to AD (99). 
Cleaved protein from the gene APP forms plaques in the brain and causes AD. In this study, 
cDNA of the APP was recombined back into the genome, possibly contributing to the 
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Table 3: Overview of studies on somatic mutations in AD brains 
Samples Targets Brain-specific SNVs in 
AD brains 
Reference 
52 AD and 11 non-AD – 
blood and brain 
Deep exome sequencing 
(584x) 
595 brain-specific SNVs (71) 
17 AD and 4 non-AD – 
blood and brain 
Exome sequencing ~575 SNVs/patients (98) 
20 AD brains 
Exons of 56 genes linked to 
common neurodegenerative 
disorders (genes include 
APOE, APP, PSEN1, 
PSEN2, SORL1, UNC5C) 
15 brain SNVs in 9 AD 
brains – none in AD 
candidate genes 
(65) 
7 AD and 7 non-AD brains APP gene Somatic gene recombination (99) 
100 AD brains and 355 
blood from 445 AD 
11 AD candidate genes 
(APP, PSEN1, PSEN2, 
VPS35, MARK4, SORL1, 
BACE1, NCSTN, PSENEN, 
APH1A, APH1B) 
Two brain-specific SNVs: 
one in the APP gene, and one 
in the SORL1 gene 
(66) 
72 AD and 58 non-AD 
brains 
4 AD candidate genes, 10 kb 
upstream and downstream 
(APP, PSEN1, PSEN2, 
MAPT) 
Two SNVs in the MAPT 
gene, and one in the PSEN2 
gene 
(67) 
1 AD brain PSEN1 
Somatic and germline 
mosaicism of SNV in PSEN1 
exon 12  
(68) 
 
Somatic mutations have been suggested to contribute to kidney and cardiovascular diseases 
(54). They have been detected in patients with polycystic kidney disease (100), and milder 
cases of Alport syndrome have been linked to mosaicism (54). Mutations in vascular smooth 
muscle cells (VSMCs) in the arterial wall have been proposed to contribute to atherosclerosis 
where they are believed to lead to the formation of plaques in the arterial wall (101-103). 
Clonal expansion has been reported in several tissues leading to patches of cells from the 
same single cell (24, 104). Similar has been shown in the arterial wall where cells in the 
medial layer hyper-proliferate as a response to injury (102, 103). Therefore, cells carrying 
somatic mutations can be clonally expanded in the tissue and contribute to its decline. 
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2 AIMS 
The aim of this thesis was to improve the understanding of genetic events in the development 
of aging and age-associated disease by studying somatic mutations in human biopsies. This 
aim was further divided into specific aims: 
 
− To establish a genetic atlas of somatic mutations in various healthy human cells at 
young and old ages (papers I and II) 
 
− To identify mutational patterns related to specific cell types and better understand 
mutagenesis in various tissues (paper I and II) 
 
− To develop a bioinformatic strategy to identify somatic mutations in bulk tissue 
(paper III) 
 
− To identify somatic mutations in the temporal cortex of early and late-onset AD 
patients and non-AD individuals using ultra-deep sequencing of candidate genes and 
non-coding regions and tailored bioinformatic analysis (paper III). 
 
− To analyze the expression of progerin in the arteries of CKD patients and the 
occurrence of the LMNA c.1824C>T mutation as the cause of it. Consequently, to 
analyze the possible contribution of progerin accumulation to the disease 
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3 METHODOLOGY 
3.1 MATERIAL 
3.1.1 Human samples (Papers I-IV) 
The studies in this thesis were all approved by the regional committee of ethics in Stockholm 
and adhered to the statutes of the Declaration of Helsinki.  
In paper I, blood and biopsy from the leg muscle vastus lateralis were collected from three 
young (21-24 years) and four old (64-78 years) healthy individuals. From the biopsies, single 
satellite cells (SC/SkM) were expanded in culture and 29 clones sent to whole genome 
sequencing along with the blood samples. In addition, four satellite clones were sequenced as 
a positive control for culture-induced variants after being kept in culture for 50 days.  
In paper II, blood and multi-tissue biopsies were collected from three living kidney donors of 
younger age (30-38 years) and three of older age (63-69 years). From the biopsies, in total 69 
single-cell clones from the kidney tubules (KT), subcutaneous fat (SAT), visceral fat (VAT) 
and the keratinocytes (EP), as well as the blood, were subjected for whole genome 
sequencing. 
In paper III, blood and brain temporal cortex were obtained from four early-onset (59-68 
years), four late-onset (79-89 years) AD patients, and eight age-matched (53-88 years) non-
AD individuals. In total 32 samples were subjected for ultra-deep targeted sequencing. 
In paper IV, arteries were collected from 40 CKD patients (20-69 years) and eight controls 
(47-68 years) for immunofluorescence/immunohistochemistry (IF/IHC) staining and RNA 
extraction. Blood was obtained from 26 of the 40 CKD patients and 26 additional controls 
(21-81 years) for rare mutation detection. 
3.1.2 Cells and animal models (Paper IV) 
Lymphoblastoid and dermal fibroblast cell lines were obtained through the Coriell Cell 
Repository, Progeria Research Foundation and the International Werner Syndrome Registry. 
Tissue samples originated from individuals with progeria and each cell line carried a variant 
in the LMNA gene known to cause the progeria syndrome. The purpose of keeping the cell 
lines was to use them as a heterozygote standard for testing rare event detection using 
ddPCR. 
Human primary aortic smooth muscle cells (ATCC, PCS-100-012) were used in an in vitro 
experiment where the effects of uremic serum were analyzed. 
The HGPS knock-in mouse model (105) was generated to carry a mutation in the Lmna gene 
(c.1827C>T, p.G609G) leading to progerin, equivalent to the human LMNA mutation 
(c.1824C>T, p.G608G). The mice were used to analyze the effect progerin has on cells in 
vivo.   
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3.2 LABORATORY METHODS 
3.2.1 Somatic mutations in single cells and bulk tissue (Papers I-IV) 
Different methods can be performed to identify somatic mutations (see 1.4). Here, three 
methods were used; in vitro clonal expansion of single cells (papers I and II), ultra-deep 
sequencing of bulk tissue (paper III), and ddPCR of bulk tissue (paper IV). 
In papers I and II, tissue biopsies were obtained and immediately digested to obtain single 
cells. The cells were plated and expanded in culture to obtain enough DNA for whole genome 
sequencing. Blood was collected from the same individuals and DNA extracted for whole 
genome sequencing. To validate the cell types, the cells were FACS sorted before culturing 
(paper I), and a selection of cultured clones was validated with q-PCR (paper I and II).  
In papers I and II, the library preparation was performed using 25 ng of DNA starting 
material and a semiautomatic NeoPrep station using the Illumina TruSeq Nano Kit. The 
libraries of the blood DNA were prepared with Illumina TruSeq PCR-free library 
preparations. Sequencing was performed at NGI Sweden, Science for Life Laboratories, 
Stockholm, on Illumina HiSeq X, PE 2×150 bp. 
In paper III, sample libraries were created using 4 µg of DNA (that represent >600,000 cells, 
assuming 6.6 pg DNA/cell) as a starting material. High amount of DNA was used to obtain 
the complexity needed to be able to detect rare mutations. The sample libraries were 
hybridized to an array containing regions linked to AD and consisted of 2.86 MB of the 
human genome.  
The average output from a HiSeq 2500 lane is 143 million reads. The sequencing was paired-
end with an insert size of 125 bp and the target region was 2.86 MB. The 32 libraries were 
run in two pools, each consisting of 16 equal sample libraries. To estimate the average base 
coverage following formula was used: 143 𝑀 𝑟𝑒𝑎𝑑𝑠 ∗ 2 𝑝𝑎𝑖𝑟𝑒𝑑 𝑒𝑛𝑑 ∗ 125 𝑏𝑝 𝑖𝑛𝑠𝑒𝑟𝑡 𝑠𝑖𝑧𝑒2.86 𝑀𝑏 𝑡𝑎𝑟𝑔𝑒𝑡 𝑠𝑖𝑧𝑒 ∗ 16 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑜𝑜𝑙  
In paper III, 32 sample libraries were individually captured on the sequencing array according 
to the provided protocol from the manufacturer (Roche, USA). 
In paper IV, we used ddPCR to detect somatic mutations in arteries and blood of CKD 
patients and controls. DdPCR is a sensitive method to detect rare alleles in the presence of a 
common allele in a mosaic tissue sample (69). The solution is partitioned into 20,000 droplets 
containing the DNA sample and probe assay for the wild-type and mutant allele. The PCR 
amplification occurs within the droplets, which facilitates the detection of these rare events. 
The fluorescence light from the probes is then read, and the concentration and fractional 
abundance of the mutant allele calculated. DdPCR assays for SNVs in the LMNA gene and 
non-LMNA genes were designed and run on DNA from the arteries and blood of the CKD 
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and controls. Furthermore, assays were designed for non-LMNA SNVs that have similar 
effects on their respective protein as the LMNA SNVs have on the lamin A protein. 
3.2.2 Validation of somatic mutations (Papers I, III, IV) 
The ddPCR technology was used in papers I and III to validate the somatic mutations 
identified with sequencing, in paper IV to detect somatic mutations and in papers I and IV for 
absolute quantification.  
The assays were designed and ordered from BioRad’s web interface for absolute 
quantification (primer assays in paper I and IV) and rare event detection (primer-probe assays 
in paper I, III and IV). The procedure of droplet generation was performed according to the 
manufacturer’s recommendations and the raw fluorescence data analyzed and exported from 
the manufacturer’s software (QuantaSoft version 1.6, Bio-Rad). The samples were run in one 
or more wells, depending on DNA availability. When more than one well was tested for the 
same sample/assay, the replicated wells were merged.  
3.3 BIOINFORMATIC ANALYSIS 
3.3.1 Somatic variant identification (Paper I, II, III) 
In total, whole-genome sequencing was performed on 40 samples for paper I, and 75 samples 
in paper II. In addition, ultra-deep sequencing on genomic regions covering in total 2.86 MB 
was done on 32 samples for paper III. This resulted in a large amount of data to be analyzed. 
Two pipelines were developed to identify somatic mutations in clonally expanded cells 
(papers I and II) and bulk tissue (paper III) (Figure 7). 
For both pipelines, the raw files were processed in the same way (Figure 7, left panel). The 
raw files from the sequencer (BCL) were transformed to FASTQ files using the software 
bcl2fastq (www.illumina.com). The FASTQ files contain the raw unmapped reads as well as 
the sequence quality score and are in a format that could be further processed. The FASTQ 
files were aligned to the reference genome using Burrow-Wheeler aligner (BWA, (106)). The 
mapped BAM reads were checked and marked for PCR duplication, the base quality scores 
were recalibrated and indels were identified and the reads realigned. These steps are part of 
GATK Best Practices (107) and were performed to improve the variant calling.  
To identify somatic mutations in clonally expanded cells (Figure 7, middle panel; papers I 
and II), three callers were used: HaplotypeCaller (107), MuTect2 (58) and Fermikit (108). 
Variants, SNVs and indels, that were identified by all three callers were subjected for further 
analysis as shown in figure 7. Each clone was compared to matching blood sample to identify 
somatic mutations in each cell.  
To identify somatic variants in bulk sequencing (Figure 7 right panel; paper III), four 
different somatic callers: MuTect (58), MuTect2 (58), Strelka2 (73), and Varscan2 (72), were 
used in “somatic mode” with brain as tumor and blood as normal. Problematic regions 
containing segmental duplication, as well as variants with the comments “clustered events”, 
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“poor mapping region”, “nearby gap”, “triallelic sites” and “strand artifact” from the MuTect 
callers were excluded. All variants identified, both germline and somatic, were further 
analyzed using the custom made somatic filtering showed in figure 7.  
 
Figure 7: Schematic bioinformatic pipelines used in this thesis for identification of mutations in 
clonally expanded single-cells and in bulk tissue. “Processing of raw files” (Papers I-III), 
“Clonally expanded single-cells” (Papers I-II) and “Bulk sequencing” (Paper III). BCL: binary 
call files; BWA-mem: Burrow-Wheeler aligner; VEP: Variant Effect Predictor; AA: alternative 
allele; AAF: alternative allele frequency. 
3.3.2 Mutational signatures and genomic distribution (paper I, II) 
Analysis of mutational signatures was performed using the R packages MutationalPatterns 
(76) and NMF. Non-negative matrix factorization (NMF) was used where the cophenetic 
correlation coefficients determined the number of de novo mutational signatures needed. To 
understand the mechanism behind the de novo signatures, they are compared with the 
COSMIC signatures and the similarities between the mutational profiles calculated (76).  
Analysis of the genomic distribution of mutations was performed in two ways:  
1) To investigate the mutational enrichment or depletion in exons, introns, regulatory and 
conserved regions the R-package MutationalPatterns (76) was used. Information about 
tissue-specific genes was obtained from the Human Protein Atlas (http://proteinatlas.com) 
and conserved regions (PhastConsElements46way data) were downloaded from the UCSC 
genome browser. In short, coverage files were obtained for every sample, as well as the total 
number of somatic mutations identified in each sample. First, the probabilities (Prob) were 
calculated based on the total number of mutations (Nmut) and total bases covered (Bcov).  
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𝑃𝑟𝑜𝑏 =  𝑁!"#𝐵!"#  
Then the expected number of mutations (Exp) within the region were calculated where the 
probabilities were multiplied with total numbers of bases within the region of interest (BROI): 𝐸𝑥𝑝 = 𝑃𝑟𝑜𝑏 × 𝐵!"# 
From the observed (Obs) and expected (Exp) numbers of mutations, log2(Obs/Exp) was 
calculated, where negative numbers represent mutation depletion and positive numbers 
represent mutation enrichment. Binominal test was used to obtain the P-value. 
2) To investigate the relationship between the mutations and replication 
timing/H3K36me3/transcriptional levels/CTCF motif, regression analysis was performed 
(109, 110). The data on replication timing was obtained from the ENCODE project 
(RepliSeq) and divided into 6 bins ranging from the latest replicating (bin 0) to the earliest 
replicating (bin 5). The transcriptional (RNA-seq) levels and H3K36me3 histone marker were 
collected from Roadmap. Each dataset was divided into 4 bins, ranging from 0, containing 
non-expressed regions and absent from H3K36me3, up to bin 3 containing high expressed 
regions and highest abundance of H3K36me3.  
3.3.3 In silico analysis of mutation effect (Paper I, II, III) 
Majority of the mutations detected are located in introns or outside genes. Therefore it can be 
hard to estimate the effect of the mutations. Different sources are available online where it is 
possible to determine if the mutation is likely to have a damaging effect, or if it is located 
within an enhancer or transcription factor binding sites. 
In paper I, data from the FANTOM5 project (fantom.gsc.riken.jp/data) was used to analyze 
regions that are expressed during myoblast to myotube differentiation. In paper I and II, 
CADD (Combined Annotation Dependent Depletion, (111)) was used to annotate the somatic 
variants, and Panther GO slim overrepresentation test (pantherdb.org) to identify 
overrepresented biological processes. 
In paper III, candidate enhancers and transcription factors were obtained using GeneHancer 
(112) PROMO v3.0.2 (113, 114) and JASPAR v5.0_ALPHA (115).   
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4 ETHICAL CONSIDERATION 
The use of human research subjects always requires consideration of ethical issues and is 
monitored by Ethical Review Boards. In this thesis, studies on human samples were 
conducted in all four papers. All the participants (or a next of kin acting as a proxy) gave their 
informed consent and participated voluntarily in the study.  
In paper I, the biopsies were obtained exclusively for the purpose of the study. The sampling 
was performed to be as painless as possible for the individual. In paper II and IV, the biopsies 
were obtained during already planned surgeries and did not add to more discomfort for the 
individuals. In paper III, the brain was collected post-mortem.  
In paper IV, mice were used as an animal model. The experiments were essential to verify the 
biological process, previously observed in vitro. The Ethical review board approved the 
animal studies, and all procedures were performed in accordance with the institutional 
guidelines and regulations. Minimum amounts of animals were used in the experiment, and 
animal health carefully monitored. 
Furthermore, sequencing data from a living individual is considered sensitive personal data 
that follows strict legislation in Sweden, as with the new EU’s General Data Protection 
Regulation (GDPR). The data has been kept in a protected server with a double 




  22 
5 RESULT AND DISCUSSION 
The thesis consists of four studies, where somatic mutations in human cells and their 
contribution to age-related diseases have been analyzed. In this section, the most relevant 
findings are summarized and discussed.  
5.1 PAPER I  
Rationale and study design 
Somatic mutations accumulate with increased age and are believed to lead to functional 
decline. Although mutations in healthy cells have been studied (21-34), several questions are 
still unanswered. The occurrence of somatic mutations and its downstream effect of somatic 
mutation burden in the skeletal muscle (SkM) or its resident stem cell population (the satellite 
cells, SCs) were largely unknown. In paper I, the aim was to study somatic mutation 
accumulation in human SCs, analyzing the muscle of young and old healthy individuals.  
Muscle biopsies from young (21-24 years, n=3) and old (64-78 years, n=4) healthy 
individuals were collected and single satellite cells clonally expanded in culture. In total, 29 
SCs were subjected to WGS along with the blood sample from the same individuals. In 
addition, a subset of SCs was kept in culture for 50 days to analyze the effect of long-term 
culturing and culture-induced mutations. A bioinformatic pipeline was developed to identify 
somatic mutations in SCs. The distribution of somatic mutations, their age-related 
accumulation and the somatic mutational patterns were analyzed to understand the effect of 
somatic mutagenesis on the aging of the skeletal muscle. 
With increased age, satellite cells accumulate mutations that propagate into the muscle 
and might contribute to functional decline  
Somatic mutations in SCs increase with aging. An individual in his 20’s has around 200 
SNVs/SCs and an individual in his 80’s has up to 1300 SNVs per SC (Table 4). Through our 
data, we calculated a mutation rate of 13 SNVs/genome/year in SCs. 
The mutations showed a pattern that has been previously linked to aging. Around 25% of the 
mutations observed in SCs were contributed by signature 1, and around 45% of the mutations 
by signature 5. The remaining 30% were contributed by signature 8. In old SCs, the fraction 
of signature 5 was higher than in younger cells, while the fraction of signature 1 and 8 
remained the same in young and old. Signature 18 has previously been linked to in vitro 
stress during cell culture and was observed in long-culture SCs. 
In agreement with the protection of the functional regions of the genome from mutations (see 
1.3), fewer mutations than expected were observed in exons and regulatory regions. 
Interestingly, this protection was somewhat lost in the older cells, potentially due to less 
efficient DNA repair machinery during aging. We observed that a higher mutation burden 
resulted in a slower proliferation of the cells from older muscles and that somatic mutations 
can propagate into the skeletal muscle. A variant found in one SC was found in 1.3% of the 
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alleles of genomic DNA and 1.9% of the RNA transcripts of the muscle biopsy from which 
the SC originated.  
In summary, somatic mutations accumulate in the SCs with aging. We observed a loss of 
genome integrity with increased age where regions essential for SCs were more affected in 
the older individuals compared to the younger. A somatic mutation identified in one of the 
SCs was detected in the muscle biopsy (on both DNA and RNA level), indicating that the 
genomic defects observed can be propagated to the muscle. Hence, the accumulation of 
somatic mutations in the SCs might contribute to the age-related decline observed in muscle 
mass and function. 
5.2 PAPER II 
Rationale and study design 
Although inter-individual mutagenesis is well studied, not much is known about the intra-
individual genetic variation. For example, cells within the same tissue are believed to be 
exposed to the same mutagens and consequently show similar somatic mutation patterns. 
However, a comprehensive analysis of healthy tissues is still lacking. In paper II, the aim 
was to study somatic mutation accumulation in different tissues from the same individual, as 
well as to analyze mutagenesis among different tissues and ages. This provides information 
about the tissue-specific mutagenesis while excluding the variability due to different genetic 
background and environmental exposure. 
Multi-tissue biopsies were collected from living kidney donors of younger (30-38 years, n=3) 
and older (63-69, n=3) age (Figure 8A). From the collected tissues (kidney tubules (KT, 
n=25), subcutaneous fat (SAT, n=22), visceral fat (VAT, n=20) and epidermis (EP, n=2)) 
progenitor cells were collected and clonally expanded in culture (Figure 8B). The 
bioinformatic pipeline created for paper I was used here to identify somatic mutations in 
different tissues and the mutational patterns analyzed. In addition, publicly available WGS 
data on healthy cells, generated with a similar strategy as in papers I and II, were used to 
explore the mutational profile in different tissues. Somatic mutations from tissue-matched 
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Figure 8: A) Experimental strategy used in paper II. Blood, kidney, subcutaneous fat (SAT), 
visceral fat (VAT) and skin (EP: epidermis) biopsies were obtained from living kidney donors. 
The blood was whole genome sequenced and used for germline variant detection. Single 
progenitor cells from kidney tubules, SAT, VAT and EP were clonally expanded in culture and 
whole-genome sequenced.   B) Schematic summary of the sequenced samples. Two to five 
single genomes per biopsy were sequenced from six individuals.  












Skeletal muscle 21-78 29/7 266-1473 13/year 11-114 Paper I 
Kidney tubules 1 30-69 11/6 342-1131 12/year 25-116 Paper II 
Kidney tubules 2 31-69 14/5 807-4132 57/year 56-582 Paper II 
Epidermis 69 2/1 1510;1639 na 28;32 Paper II 
Subcutaneous fat 30-69 22/5 438-1558 17/year 36-109 Paper II 
Visceral fat 30-69 20/4 684-2133 27/year 40-127 Paper II 
Age: age range of individuals used in the studies; Samples/Individuals: number of samples and 
individuals used in the studies. SNVs per sample: range of the SNVs identified in the samples, 
normalized to coverage. The SNV rate shows SNVs accumulated every year. Indels per sample: 
range of the indels identified in the samples, normalized to coverage.  na: not available. 
Progenitor cells accumulate somatic mutations at different rate. A specific population of 
kidney tubule cells shows mutation enrichment in kidney-expressed genes and 
regulatory regions. 
Somatic mutations were detected in all progenitor cells and, as observed in satellite cells 
(SkM: skeletal muscle) in paper I, increased with aging (Table 4). Although we had cells 
from four different tissues (KT, SAT, VAT, EP), analysis on the mutational context (i.e., tri-
nucleotide context) showed that KT cells were divided into two groups (Figure 9A). The EP 
cells showed strong UV-induced mutagenesis with many C>T mutations while part of the KT 
cells, called KT2, showed fewer C>T mutations than SAT, VAT and the remaining KT, 
called KT1. Furthermore, a yearly increase of mutations was higher in KT2 cells (56.6 SNVs 
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and 8.0 indels per genome per year) compared to the other cell types (KT1 clones 11.7 SNVs 
and 1.4 indels; SAT 17.5 SNVs and 0.9 indels; VAT 27.2 SNVs and 1.4 indels) (Figure 9B).  
 
Figure 9: A) Heatmap showing the clustering of the 69 single genomes based on their tri-
nucleotide context (vertical) and the relative amount of mutations in each category (horizontal).  
B) Average yearly increase of somatic SNVs and indels per tissue. C) Enrichment (upward bars) 
or depletion (downward bars) of somatic mutations in indicated genomic regions. # P< 0.05 one-
sided binomial test; * P<0.05, ** P<0.01, *** P < 0.001 one-way ANOVA or two-sided t-test. 
EP=epidermis; KT1=kidney tubule 1; KT2=kidney tubule 1; SAT=subcutaneous fat; 
VAT=visceral fat  
The mutations identified in KT2 cells were more likely to be pathogenic than those observed 
in other cell types obtained from the same donor. In the KT2 cells we observed mutational 
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enrichment in kidney-expressed genes (exons and introns) and regulatory regions, while KT1, 
SAT, and VAT cells showed mutation depletion in their tissue-expressed genes and 
regulatory regions. Similarly, we observed that while conserved regions were protected from 
mutations in KT1, SAT and VAT, they were enriched for mutations in KT2 cells (Figure 9C).  
Meta-analysis of somatic mutations in healthy tissue identifies basal and mutagen-
induced mutational patterns 
To build a comprehensive atlas of somatic mutagenesis of healthy cells in different tissues, 
the analysis was extended to available datasets obtained from clonally expanded cells. 
Previous mutational analyses had been performed on stem cells from liver, intestine and 
colon (21), skin fibroblasts (25), blood progenitors (30) and the SkM satellite cells and long-
cultured SkM satellite cells from paper I. These genomes, in total 92, were added to the 
analysis, as well as WGS data from tissues-matched cancer cells (n=192). Unsupervised 
clustering on the mutational context showed that KT1, SAT, VAT, SkM and blood clustered 
together, indicating similar mutational signatures. They were defined as “common 
progenitors” and grouped for further analyses (Figure 10). In addition, we could observe that 
cancer genomes often clustered in near proximity of their tissue-matched healthy genome.  
 
Figure 10: tSNE plot of the tri-nucleotide context of the somatic SNVs observed in the 69 
genomes from EP (epidermis), KT1 (kidney tubule 1), KT2 (kidney tubule 2), SAT 
(subcutaneous fat), VAT (visceral fat), as well as the 92 genomes from skeletal muscle (SkM, 
paper I), and from public datasets: liver, intestine and colon (21), skin fibroblasts (25), blood 
progenitors (30).  
Mutational signatures were analyzed for 353 WGS genomes included in the meta-analysis. 
By applying the most recent classification of mutational signatures (81), we could identify 
eight mutational signatures. Overall, three main signatures (signature 1, 3/8 and 5) were 
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identified in all cell types (Figure 11) and increased with aging. We defined this signature 
combination as a “basal mutagenesis” representing the inevitable result of the core cellular 
process. However, the contribution of these three signatures to the mutation burden of each 
genome was different depending on the cell type. Signature 1, 3/8 and 5 contributed to the 
majority of the mutations detected in the common progenitors (blood, SAT, VAT, SkM and 
KT2). The mutations detected in the intestine and colon samples were mostly signature 1, 
while the KT2 and liver samples showed a low signature 1 contribution but higher signature 5 
(Figure 11). That is in agreement with signature 1 detected in cells with a high proliferation 
rate, while signature 5 is more prominent in slower dividing cells (21, 59).  
 
Figure 11: The relative contribution of the eight mutational signatures in healthy cells. The basal 
mutagenesis, defined as signatures 1, 3/8 and 5, are showed together while specific mutagenic 
signatures are pulled out from the pie chart. In the box to the right are the long culture skeletal muscle 
cells as well as the skin fibroblasts, both that were kept long in culture and showed higher proportion 
of signature 18, linked with in vitro culture stress. These results need to be taken with some 
consideration; the data is taken from different studies where different analyses were conducted to 
identify somatic mutations. Small shifts in the relative distribution of signatures might occur. Bold 
marked tissues represent data presented in paper I and II. Other tissues are colon, intestine and liver 
(21), blood (30) and skin fibroblasts from IPS (25). 
  28 
Other cells showed specific signature induced by tissue-specific mutagens. In the skin, most 
mutations were contributed by signature 7a; a strong UV-induced signature and observed in 
melanoma cancer. Consistently with that melanoma cancer cells clustered in close proximity 
of the healthy epidermal cells. Skin fibroblast (25) and skeletal muscle cells from paper I that 
were kept long in culture (SkM_long) showed high contribution of signature 18, previously 
linked to in vitro mutagenesis (21). Signature 40 was mainly observed in KT2 as well as in 
the two kidney cancers (clear cell and papillary renal cell carcinoma (KIRC, KIRP)).  
KT2 cells originate from the proximal tubules  
To further define the subsets of KT2 and KT1, markers for different kidney cells were tested 
using FACS and qPCR. Both KT1 and KT2 expressed the markers of kidney progenitors 
(CD133, CD24 and PAX2). KT2 clones expressed the markers of proximal tubules, while the 
KT1 clones were generally negative for all markers of differentiated kidney tubule cells. No 
kidney clones expressed markers of distal tubules. A marker of tubule damage was observed 
at different degrees in all KT clones, especially in KT2.  
 
Figure 12: Average yearly increase of somatic SNVs in different tissues of the human body. 
Bold marked tissues represent data presented in paper I and II, other tissues as reported in 
representative studies (see figure 4 and table 2 in chapter 1.6). These results need to be taken 
with some consideration; different experimental methods and bioinformatical analyses were 
performed in these studies and could affect the outcome. Colon, intestine and liver (21), 
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HSPCs (hematopoietic progenitor cells)(59), B-lymphocytes (33), skin (32), colorectal (29), 
brain PFC (prefrontal cortex) and hippocampus (27), esophagus (24), endometrium (31). 
Taken together, here we present whole genome sequencing data and high confident somatic 
variants. All cells were clonally expanded single human cells and provide a reliable 
comparison of tissue-specific differences. Compared to previously published data (see 1.6), 
the progenitors of SAT, VAT, SkM and KT1 show a yearly accumulation similar to that 
observed in most tissues, while the mutation accumulation in KT2 cells is among the highest 
reported in healthy cells (Figure 12).  
Previously, signatures 1 and 5 have been described as the clock-like signatures representing 
the unavoidable mutational accumulation in cells with aging (26). Here, we expand that 
concept and define “basal mutagenesis” as a combination of signatures 1, 5 and 3/8 
displaying the inevitable mutation accumulation as consequences of core cellular process 
during aging. In addition, we observed tissue-specific mutagens where signature 7 (high UV-
induced mutations) was observed in EP and signature 18 (in vitro cell culture stress) in cells 
kept long in culture (SkM-long and SkinFB).  
KT2 cells showed a mutational profile previously linked to clear cell and papillary cell renal 
cell carcinoma (KIRC and KIRP, respectively). These two kidney cancers originate from the 
proximal tubules, while the third kidney cancer tested, chromophobe renal cell carcinoma 
(KICH), originate from the distal tubules and cluster away from KT2 and KT1. Overall, 
based on the analysis of mutational patterns and expression markers, we conclude that KT2 
are cells located in the proximal tubules, while KT1 are uncommitted progenitors of the 
kidney tubule. 
Common progenitors apart from KT1 (e.g. SAT, VAT, SkM and blood) showed mutation 
depletion in early replicated regions, open chromatin (defined as H2K36me3-rich) and 
transcribed genes. However, in KT2 cells, this pattern was altered where early replicated 
regions, open chromatic and transcribed genes were not as protected from mutations as the 
other cells. Notably, highly transcribed genes were enriched for mutations in KT2 cells and 
showed an altered pattern of transcriptional-strand asymmetry. Together this indicates that 
the DNA repair mechanism is active in the common progenitors, while some form of 
transcription-coupled mutagenic processes (116) was observed in KT2 cells and MMR was 
not as effective as in common progenitors. 
In summary, genome-wide analysis on somatic mutagenesis in human cells provides an 
understanding of the changes in genome integrity during aging and elucidates the mutagenic 
process occurring within the cells of our body.  
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5.3 PAPER III 
Rationale and study design  
Alzheimer’s disease (AD) is a common neurodegenerative disease classified into early-onset 
and late-onset AD. Familial cases are known with suggestive genetic causes; however, most 
AD cases are sporadic with unknown causes. Most studies have been done on blood, 
searching for germline risk factors (117); however, recent studies have shown that somatic 
mutations accumulate in the brain of AD patients (66-68, 98) although pathogenic 
consequences of those variants are unknown. In paper III, the aim was to identify somatic 
mutations in the brain of AD and non-AD individuals.  
Blood and brain (temporal cortex) samples were obtained from early-onset and late-onset AD 
patients (n=8) as well as age- and gender-matched non-AD individuals (n=8). Eleven 
genomic regions containing 28 genes and regulatory regions, in total 2.86 MB, were selected 
for targeted sequencing. These regions contain AD candidate genes or regions that have been 
linked to AD by association studies (117). Bioinformatic analysis was performed using four 
different somatic callers (MuTect1 (58), MuTect2 (58), Strelka2 (73) and Varscan2 (72)) and 
downstream filtering was applied to identify tissue-specific somatic SNVs in the brain (see 
3.4.1). 
Somatic mutations were identified in the brain of AD patients 
The sequencing libraries were created using 4 µg of genomic DNA, which represent over 
600,000 cells (estimating 6.6 pg/cell). This high DNA input resulted in an average coverage 
of 698X ± 23X (mean ± SEM) across the captured targets. The tailored bioinformatics 
pipeline created for this study consisted of four callers, where variants were further filtered 
based on, among others, read depth and alternative allele depth.  
In total, 11 brain-specific SNVs were identified in the temporal cortex in the AD brains and 
none in the controls. One of the SNV was identified by all the four somatic callers, and the 
remaining 10 were identified by three of the callers. The SNV identified by all callers, 
chr1:207461994C>T, is located upstream of the CD55 gene and was detected at 1% allele 
frequency in the sequencing. It was validated to be present at 0.4% allele frequency in the 
brain of a late-onset AD patient but not in the blood. It was not detected in the brain of the 
other individuals. In silico analysis predicted the variant to affect transcription factor binding 
sites upstream of the CD55 gene. The CD55 gene is an inhibitor of the complement system, a 
branch of the immune reaction whose function has been linked to AD (118-120). 
Few brain-specific mutations have been found in AD brain samples (65, 66). Identifying 
somatic mutations in bulk DNA is challenging and limited to parts of the genome (65-68, 98). 
However, a recent study suggests that using LCM to enrich neurons is a promising method to 
identify brain-specific mutations (71).  
For this study, the default settings of the somatic callers proved to be too strict and therefore a 
tailored downstream bioinformatics analysis was created. This study emphasizes the need to 
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create somatic mutation callers that are not designed for cancer analysis but to analyze rare 
somatic mutations in bulk DNA. 
Taken together, somatic mutations occur in the brain and can be detected at low frequency 
using ultra-deep sequencing and comprehensive bioinformatic downstream analysis. Our 
results suggest that targeting regulatory regions in addition to the exons could increase the 
understanding of the molecular basis of both early- and late-onset AD. The confirmed variant 
might contribute to AD via the regulation of the complement system, however further studies 
are needed to confirm the significance of the findings for AD disease pathogenesis. 
5.4 PAPER IV 
Rationale and study design 
Children born with the Hutchinsons-Gilford progeria syndrome (HGPS; progeria) show 
clinical features of premature aging like growth retardation, loss of subcutaneous fat and 
fragile bones (16). The main cause of progeria is a mutation in the LMNA gene, c.1824C>T 
(14, 15). The mutation creates a cryptic splice site leading to a 150 bp deletion that results in 
a truncated LMNA protein called progerin. The children have severe cardiovascular diseases 
and die in their teenage years from cardiovascular complications (16). 
The vascular phenotype observed in the HGPS children is very similar to that observed in 
individuals with end-stage CKD. Pathology changes consist of tissue degeneration of arteries 
(Figure 13A: cross-section of an arterial wall) and include intima thickness, media 
calcification, loss of VSMCs and adventitial fibrosis (121, 122). These phenotypic 
similarities could indicate a shared component between these two different conditions. 
Indeed, progerin expression has been found at low levels in healthy tissues, including arteries 
(122-124). In paper IV, the aim was to analyze the presence of progerin in the arteries of 
CKD patients and its causes and contribute to the disease. 
Arteries were collected from CKD patients (n=40) and controls (n=8), to assess the frequency 
of progerin positive cells in the tissue. Calcification of the arteries was classified, and cell 
density measured. The arterial sections were tested for markers of inflammation, cell 
proliferation, senescence and DNA damage. To assess the somatic mutations in the LMNA 
gene that lead to progerin, DNA from artery sections (CKD n=40, controls n=6) and blood 
(CKD n=26, controls n=26) were collected. 
Progerin and the LMNA c.1824C>T variant are observed in the CKD arteries 
Increased calcification was observed to correlate with increased age, and reduced cell density, 
especially in the arterial media of the CKD patients. Progerin positive cells were identified in 
28 out of 40 patients with a frequency of 0.2-7.4%. The majority of the cells were scattered in 
the media, while clusters of positive cells were observed in two of the patients (Figure 13B).  
The frequency of progerin positive cells correlated with years of disease (Figure 13C), but not 
with age at sampling. Out of six control arteries, only one showed weak progerin staining. 
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The presence of progerin was further confirmed with the detection of the progerin transcripts 
in all CKD tested (n=19) but none of the controls (n=8).  
 
Figure 13: Progerin in CKD arteries and its effect in vivo. A) Cross-section of the arterial wall. The 
innermost layer, tunica intima, is a simple epithelial layer, the middle layer, tunica media, contains 
VSMCs, and the outer layer, tunica adventitia, contains elastic fibers. B) Clusters of progerin positive 
cells in the tunica medium of CKD arteries. Scale bars: 10 µm. C) Frequency of progerin positive 
cells (y-axis) in all CKD patients showed a correlation with the number of years of disease (x-axis), 
especially in CKD patients with calcification grade 1. D) The progerin protein, progerin transcript or 
the LMNA c.1824C>T mutation was detected in 34 out of 40 CKD patients and one out of eight 
control. E) Frequency of DNA damage measured with 53BP1 (x-axis) correlated with progerin 
positive cells (y-axis) (n=14). F) Frequency of CD45.2 population from LmnaG609G/G609G (red, 
n=5) and wild-type (blue, n=4) mice in recipient wild-type mice at 4, 8, 12, 16 and 30 weeks after 
transplantation. Data are shown as mean and SEM. 
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To identify the underlying molecular mechanism for the progerin expression in the CKD 
arteries, we designed a ddPCR assay to analyze the presence of the LMNA c.1824C>T 
variant. DNA was isolated from the paraffin-embedded slides containing the epigastric 
arteries from the 40 CKD patients and the six controls previously stained for progerin. The 
DNA isolation was successful for 27 CKD and one control. The variant was detected in 16 
CKD patients and one control; the same control as previously had shown weak progerin 
staining. The fractional abundance of the variant ranged from 0.73%-47.8%. In total, we 
detected the progerin expression or the progerin variant (LMNA c.1824C>T) in 34 out of 40 
CKD and 1 out of 8 controls (Figure 13D). 
Increased proliferation and DNA damage in the CKD arteries 
The arterial tissue is characterized by low regeneration in basal conditions; however, 
increased proliferation is observed as a response to tissue damage (102, 103).  Staining for 
PHH3, a marker of increased proliferation, identified proliferating cells in nine out of 11 
CKD arteries. Most of the proliferating cells were detected in the adventitial, but as well in 
the medial layer.  
A downstream effect of progerin expression is increased DNA damage and senescence (125). 
The analysis showed a significant positive correlation between the frequency of cells with 
activated DNA damage response and the frequency of progerin positive cells in artery 
sections (n=18; r=0.63, P=0.005, and n=14; r=0.66, P=0.0097, for ATR and 53BP1 
respectively) (Figure 13E). Markers of inflammation and senescence indicated a modest 
vascular and systemic inflammation and activation of a senescence-associated secretory 
phenotype (SASP).  
The effect of the progerin mutation in vivo 
Progerin is associated with premature senescence and its accumulation has detrimental effects 
on the cell. Therefore we wanted to assess its effect on stem cells in vivo. To achieve that, we 
performed a competitive hematopoietic stem cell (HSC) transplantation in mice. This is an 
established method to test the functionality of stem cells in vivo. We used HGPS knock-in 
mice that carry the progerin mutation Lmna c.1827C>T, equivalent to human LMNA 
c.1824C>T (105).  
HSCs from 22-week-old HGPS and wild-type mice were collected. At that time, HGPS mice 
are near their endpoint and have fewer HSCs in their bone marrow than age-matched wild-
type mice. The HSCs were injected into recipient wild-type donor mice and peripheral blood 
samples collected at different time points. Flow cytometry was used to analyze the proportion 
of transplanted donor cells (CD45.2) to recipient cells (CD45.1). We observed a significant 
increased initial proliferation in the progeroid donor cells, compared to wild type donor cells. 
Moreover, the progeroid donor cells were still present 30 weeks after transplantation (Figure 
13F). These results show that HSCs with the progerin mutation are viable and do not undergo 
senescence in vivo.  
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Here we report progerin positive cells as well as the progerin variant, LMNA c.1824C>T, in 
the arteries of CKD patients. In two of the CKD arteries, clusters of progerin positive cells 
were detected, moreover, a high fractional abundance of LMNA c.1824C>T variant was 
observed in the CKD arteries (up to 47.8%). This suggests a clonal expansion of a progenitor 
cell carrying the variant leading to progerin expression. Studies have shown that somatic 
mutations clonally expand in proliferating tissue (24, 104). Although the arterial wall does 
not generally contain proliferating cells, increased proliferation was detected in the CKD 
patients. The origin of proliferating cells in the arterial wall is unknown; however, it has been 
shown that some VSMCs are capable of proliferating. They are suggested to be specific 
hyper-proliferating cells that create patches of cells originating from the same single cell 
(103), potentially carrying pathogenic mutations (101, 102).  
Expression of progerin or the LMNA c.1824C>T variant has been shown to lead to increased 
cell proliferation (126, 127); yet, progerin is toxic for the cell and high levels of progerin lead 
to senescence (128, 129). We observed that hematopoietic progenitor cells with the progerin 
mutation have initial growth advantages and do not undergo senescence.  
Taken together, progerin is expressed in the CKD arteries and might contribute to the 
vascular phenotype observed in the CKD patients. Our results suggest that the LMNA 
c.1824C>T mutation is the cause of the expression of progerin and that the mutation might 
have occurred in a VSMC or a progenitor cell activated during the vascular regeneration. The 
proliferation during vascular regeneration might have promoted the clonal expansion of 
mutated clones within the tissue. The final effect of this expansion is an increased tissue-
expression of progerin, which finally contributes to the worsening of the pathology. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVE 
Germline mutations and their contribution to diseases have been extensively studied, leading 
to the identification of genetic risk factors and improved knowledge about our genome. 
Conversely, somatic mutagenesis has only started to be explored. In addition, the study of 
somatic mutagenesis has often been limited to cancer. Very little information is available 
about somatic mutation accumulation during physiological aging, as well as in pathologies 
other than cancer. In this thesis, I analyzed somatic mutations in healthy tissues and age-
related diseases, such as Alzheimer´s disease and chronic kidney disease. This work provides 
advancement in our understanding of the mutagenesis in different tissues and its possible 
contribution to age-associated diseases. 
In paper I and paper II, we showed that somatic mutations occur in healthy tissues and the 
somatic mutation burden increases with increased age. We performed a genome-wide meta-
analysis on healthy cells from various tissues and at different ages. We characterized a 
process that we called “basal mutagenesis” and that is the consequence of mutation 
accumulation during cell core functions. Furthermore, we observed that the pattern of 
mutations in a cell is not strictly defined by the tissue of origin. In fact, even in the same 
tissue, there might be cells exposed to different mutagens that demonstrate different mutation 
patterns, as exemplified by the kidney in our study. Our results provide a better understanding 
of the processes leading to the loss of genome integrity in different tissues and during aging. 
For example, a specific cell type in the kidney (proximal tubule epithelial cell) showed a 
mutation landscape characterized by high mutation accumulation and enrichment in 
regulatory regions and expressed genes. This pattern favors the accumulation of mutations in 
functional genes, thus explaining the high propensity to cancer initiation observed in this 
particular cell type. Further analysis of mutational patterns in healthy cells and cancer will 
enhance our understandings of mutagenesis and provide new perspectives in preventing 
cancer and other age-associated diseases. Future studies will also be of importance in the 
evaluation of the functional significance of an increased mutation burden in progenitor cells 
and how that relates to reduced tissue function as seen with increased age. 
In paper III, we showed that somatic mutations occur in the brain of AD patients. It is 
challenging to detect variants at low frequency in a bulk tissue; however, we demonstrated 
that it is possible to obtain meaningful results by using ultra-deep sequencing and tailored 
bioinformatics analysis. For example, the variant upstream of the gene CD55 that we 
identified in an AD patient was predicted to affect transcription factor binding sites and might 
contribute to AD through the complement system. The importance of somatic mutations in 
age-related diseases such as AD is gaining interest, but their role in the disease process is 
unknown. Further studies are needed to analyze the effect and its contribution to AD. More 
importantly, while most studies have focused on the coding regions for the occurrence of 
somatic mutations (65, 66, 68, 71, 98), we analyzed non-coding regions including regulatory 
regions. Our results emphasize the importance of including non-coding genomic regions in 
future studies on somatic mutagenesis to increase the understanding of AD. 
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In paper IV, we identified progerin and the LMNA c.1824C>T variant in the arteries of CKD 
patients. Furthermore, we detected increased proliferation and DNA damage in these arteries. 
Our data suggest extensive vascular regeneration in the arterial wall from progenitor cells 
carrying the LMNA c.1824C>T variant. That leads to increased progerin within the tissue, 
further contributing to the disease progression.  Progerin expression has been found at low 
levels in healthy tissues (122-124), but to our knowledge, this is the first time that the LMNA 
c.1824C>T variant is detected in human samples from non-progeroid patients. Further 
analyses are needed to define how low levels of progerin affect a cell in healthy tissue. Our 
results show that somatic mutations can become a severe risk in regenerated tissues. 
Additional functional studies on the pathogenic mutation found in the CKD arteries are 
needed to understand the effect on the tissue and its contribution to the disease progression. 
Moreover, studying rare diseases like HGPS can help us to identify new treatments for more 
common diseases, as CKD. Despite being rare, several treatment strategies and clinical trials 
are currently ongoing in HGPS patients and models. Our findings suggest that those strategies 
should be tested in CKD models. 
At the beginning of my Ph.D. research studies, the mutation burden of somatic SNVs in 
healthy tissues was relatively unknown. Moreover, although it has been suggested that 
somatic mutations contribute to age-associated diseases, the identification of pathogenic 
somatic mutations has been challenging. However, during these past years, several studies 
have been published on mutagenesis in healthy cells during aging and how somatic mutations 
contribute to diseases. The studies presented in this thesis shed further light on the somatic 
mutagenesis in different tissues and cell types, and its possible consequences on the cell and 
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